Investec Asset Management LTD trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 26.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,859 shares of the medical research company’s stock after selling 654 shares during the period. Investec Asset Management LTD’s holdings in Amgen were worth $305,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of AMGN. Swiss National Bank boosted its stake in shares of Amgen by 26.5% during the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after buying an additional 551,600 shares during the last quarter. Morningstar Investment Services LLC boosted its stake in shares of Amgen by 283.8% during the 1st quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock worth $81,625,000 after buying an additional 367,894 shares during the last quarter. Karp Capital Management Corp acquired a new position in shares of Amgen during the 1st quarter worth about $54,888,000. State of Tennessee Treasury Department boosted its stake in shares of Amgen by 51.4% during the 1st quarter. State of Tennessee Treasury Department now owns 783,570 shares of the medical research company’s stock worth $128,560,000 after buying an additional 265,931 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Amgen by 31.9% during the 1st quarter. Canada Pension Plan Investment Board now owns 1,029,961 shares of the medical research company’s stock worth $168,986,000 after buying an additional 248,900 shares during the last quarter. Institutional investors own 78.09% of the company’s stock.
Amgen Inc. (AMGN) opened at 185.76 on Friday. The firm has a market cap of $135.54 billion, a price-to-earnings ratio of 16.92 and a beta of 1.35. The company has a 50-day moving average of $175.99 and a 200 day moving average of $169.31. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $191.10.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.84 EPS. Equities analysts expect that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 annualized dividend and a yield of 2.48%. Amgen’s payout ratio is currently 41.93%.
AMGN has been the subject of a number of recent research reports. ValuEngine downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $189.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Monday, June 5th. Sanford C. Bernstein set a $164.00 target price on shares of Amgen and gave the company a “hold” rating in a research note on Thursday, June 8th. Morgan Stanley raised their target price on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, June 13th. Finally, UBS AG reiterated a “neutral” rating and issued a $175.00 target price (up from $174.00) on shares of Amgen in a research note on Tuesday, June 13th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. Amgen currently has an average rating of “Buy” and a consensus target price of $186.14.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.